FDA Clearance Tracker · K252269
FINDER Flu A&B/SARS-CoV-2 Test
Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Mar 30, 2026
Substantially Equivalent
Time to decision
252 days
Received Jul 21, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Dual Track
Device class
Class II
The decision
- FDA number
- K252269
- Device name
- FINDER Flu A&B/SARS-CoV-2 Test
- Applicant
- Baebies, Inc.
- Applicant location
- Durham, NC
- Received
- Jul 21, 2025
- Decided
- Mar 30, 2026
- Decision
- Substantially Equivalent
- Submission type
- Dual Track
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3981
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QOF. The earliest in FDA's data is DEN200031, decided Mar 17, 2021.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K252269
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Baebies, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K261837 · Decided Sep 11, 2026 · 101 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
- FINDER G6PD510(k)
K201049 · Decided Sep 14, 2022 · 876 days after receipt
Device type: Glucose-6-Phosphate Dehydrogenase (Erythrocytic), Screening (JBF) · Laboratory Medicine & Pathology
- SEEKER SystemNew device typeDe Novo
DEN150035 · Decided Feb 3, 2017 · 548 days after receipt
Device type: Alpha-D-Galactosidase A (Gla) Newborn Screening Test System (PQW) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.